Skip to main content
CSPC Innovation Pharmaceutical Co.,Ltd. logo

CSPC Innovation Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 300765 ISIN · CNE100003K04 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,357 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300765

About CSPC Innovation Pharmaceutical Co.,Ltd.

https://www.xnwpharma.net

CSPC Innovation Pharmaceutical Co., Ltd. focuses on the research, development, production, and distribution of pharmaceutical products and high-end chemical ingredients. The company is a leading global supplier of caffeine and related derivatives, serving the food, beverage, and pharmaceutical sectors. Its product portfolio includes finished dosage forms such as acarbose for the treatment of type 2 diabetes, as well as various functional health products and nutritional supplements. The organization emphasizes technological innovation and quality control in its manufacturing processes, maintaining large-scale production facilities that adhere to international standards. By leveraging advanced chemical synthesis and biotechnology, the company provides essential ingredients and therapeutic solutions to a diverse international clientele, positioning itself as a key player in the global supply chain for specialized pharmaceutical components.

Recent filings

Filing Released Lang Actions
关于控股子公司乌司奴单抗注射液获得药品注册证书的公告
Regulatory Filings Classification · 85% confidence The document is an announcement by a pharmaceutical company regarding its subsidiary receiving a drug registration certificate from the national regulatory authority. It contains no financial statements, shareholder voting results, or corporate governance details. It is not a financial or management report but a compliance/regulatory announcement. Therefore, it fits the Regulatory Filings (RNS) category.
2026-05-22 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Regulatory Filings Classification · 85% confidence The document is an announcement by 石药创新制药股份有限公司 regarding the progress of using idle raised funds (募集资金) and own funds for cash management (structured deposits, large certificates of deposit, etc.). It provides detailed tables of redeemed and ongoing cash management products, approvals, risk controls, and internal oversight. This is not an earnings release, audit report, annual or interim financial report, or any management discussion of results. It is a routine regulatory announcement about the company’s use of idle funds, fitting the “Regulatory Filings” category as a general regulatory/compliance disclosure. There is no indication it is merely announcing publication of another report (RPA), nor is it a proxy, dividend notice, or share transaction. Thus it best fits Regulatory Filings (RNS).
2026-05-18 Chinese
北京海润天睿律师事务所关于石药创新制药股份有限公司2026年第二次临时股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a law firm’s legal opinion letter (“法律意见书”) on the company’s 2026 second extraordinary shareholders’ meeting, including detailed vote counts and resolutions passed. Although it is framed as a legal opinion, its content is the official declaration of voting results for each agenda item at the meeting. This best fits the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-14 Chinese
关于董事会完成换届选举及聘任高级管理人员和证券事务代表的公告
Board/Management Information Classification · 92% confidence The document is a formal corporate announcement detailing the completion of the board of directors’ re-election and the appointment of the new board members, senior management, and securities affairs representative. It does not contain financial statements, audit results, or an actual report itself, but rather announces changes in the board and management. This corresponds to the “Board/Management Information” category (MANG).
2026-05-14 Chinese
第七届董事会第一次会议决议的公告
Board/Management Information Classification · 89% confidence The document is a board resolution announcement (“第七届董事会第一次会议决议公告”) that details the election of the chairman, establishment of board committees, and appointments of senior management positions (general manager, deputy general manager, board secretary, CFO, securities representative). This clearly falls under announcements of changes in the company's board of directors or senior management, matching the Board/Management Information category.
2026-05-14 Chinese
2026年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is an official announcement of the resolutions and detailed voting results from the company’s 2026 second extraordinary general shareholders’ meeting (“临时股东会决议公告”). It lists meeting attendance, agenda items, vote counts, and outcomes for each resolution. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-14 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.